Earendil Labs Initiates Phase IIa Trial of Half-Life Extended Anti-TL1A Antibody HXN-1001 for Ulcerative Colitis
核心洞察
Earendil Labs (搜索) has dosed the first patient in a Phase IIa randomized, placebo-controlled trial evaluating HXN-1001 (搜索), a half-life extended anti-TL1A (搜索) antibody, for ulcerative colitis (搜索) treatment.
HXN-1001 (搜索) demonstrated superior efficacy compared to benchmark products in preclinical studies and showed an 8-week half-life with favorable safety profile in Phase I trials.
The antibody is formulated for subcutaneous injection at high protein concentration, potentially offering a more efficacious and convenient treatment option for IBD patients.
Earendil Labs (搜索), an AI-driven biotechnology company, has announced the dosing of the first patient in a Phase IIa clinical trial of HXN-1001 (搜索), a half-life extended anti-TL1A (搜索) antibody designed for treating ulcerative colitis (搜索). The company also completed enrollment in the Phase I trial of the antibody in healthy volunteers conducted in Australia.
Phase IIa Trial Design and Objectives
The Phase IIa trial is structured as a randomized, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HXN-1001 (搜索) in patients with ulcerative colitis (搜索). This advancement represents a significant milestone in the development of next-generation biologics targeting inflammatory bowel disease (搜索) (IBD).
Preclinical and Phase I Results
HXN-1001 (搜索) has demonstrated superior performance in preclinical testing, showing more potent efficacies in multiple in vitro assays and animal models compared to several benchmark products currently under clinical development. The antibody's design incorporates an extended in vivo half-life and high protein concentration formulation for subcutaneous injection.
Phase I study results in healthy volunteers revealed promising safety and pharmacokinetic profiles. According to Zhenping Zhu, MD, PhD, President & Co-CEO of Earendil Labs (搜索), "In the Phase I study in healthy volunteers, HXN-1001 (搜索) in single doses up to 1200 mg and multiple doses of 450 mg was well tolerated with a favorable safety profile. The antibody showed a half-life of about 8 weeks when dosed in the projected therapeutic dose range, with low incidence of anti-drug antibody response."
Therapeutic Potential and Market Position
HXN-1001 (搜索) targets TL1A (搜索), a cytokine involved in inflammatory processes associated with IBD, including both ulcerative colitis (搜索) and Crohn's disease (搜索). The combination of extended half-life and subcutaneous administration at high protein concentrations positions HXN-1001 as a potentially more efficacious and convenient treatment option for IBD patients compared to existing therapies.
Company Leadership Perspective
Jian Peng, PhD, CEO of Earendil Labs (搜索), emphasized the significance of this clinical progression: "The progression of HXN-1001 (搜索) clinical development is a significant step on our pursuit of developing next-generation best-in-class biologic therapeutics in the treatment of patients suffering from IBD. We look forward to working closely with the clinical investigators and the IBD community to advance our development programs globally and to fully realize the great potential of HXN-1001."
AI-Driven Drug Development Approach
Earendil Labs (搜索) distinguishes itself through its AI-native approach to drug development, integrating artificial intelligence across the full R&D lifecycle. The company, along with its affiliate Helixon Therapeutics (搜索), has developed a scalable platform designed to systematically generate and advance high-quality therapeutic programs targeting autoimmune diseases, cancer, and other areas of significant unmet medical need.
The company's computational innovation strategy aims to translate AI-driven discoveries into tangible clinical and patient benefits, focusing on developing protein-based biologics with potential to be first-in-class and best-in-class therapeutics. Through internal pipeline development and strategic partnerships, Earendil Labs (搜索) seeks to deliver transformative medicines to patients worldwide.